World Aquaculture Singapore 2026

June 2-5, 2026

Singapore

INTRODUCING FISH VACCINES TO NEW MARKETS – CHALLENGES AND OPPORTUNITIES

Nils O Steine*, Ben North, Terje Tingbo and Claudia Maira ?

PHARMAQ  AS, Part of Zoetis

Skogmo Industriområde , Industrivegen 50

N-7863 OVERHALLA, Norway

nils.steine@zoetis.com



Introducing fish vaccines to new aquaculture markets requires a proper understanding of epidemiology, product efficiency and value, culture and competence, technical feasibility and regul atory obstacles. Drawing on Norwegian salmon farming—where vaccination is universal and antibiotic use is minimal—this presentation highlights challenges and opportunities for expanding vaccination across finfish species globally.

Modern salmon programs may combine up to ten antigens and multiple vaccine technologies, underscoring both impact and implementation complexity. We summarize the vaccine development pathway from investigation/diagnosis and pathogen isolation, through disease impact assessment and business case evaluation, to proof-of-concept technology selection, testing and documentation of safety and efficacy, dossier preparation, regulatory review, marketing authorization, and product introduction— which  typically takes 4–7 years.

Key biological barriers include variable fish health competence, diagnostic and causation gaps, multifactorial disease with co-infections, and pathogen diversity across field types and serotypes. Technical requirements include  evaluation of onset and duration of protection , improvement of survival, growth and harvest quality, formulation stability and shelf life, and practical delivery (methods, equipment, training). Market readiness depends on local competence, farming practices, fingerling health at vaccination size, expectations and cultural barriers, and  ability and willingness to invest in vaccines. Regulatory constraints often include feasibility include permits for samples/isolates, notifiable disease reporting, genetic resource access, field trials, and marketing authorization.

Success relies on understanding  causalities of  disease,  having  access to representative isolates, understanding the value of the vaccination program ,  efficient and safe administration, and active expectation management.